Small Molecule Development & Manufacturting at Quotient Sciences

A Deep Dive Into the CMC, Technology and Financial Aspects of Successful Development of an Orally Delivered GLP-1

31 October 2024
Overview

This discussion follows on from the first in our series “Development of Orally Delivered GLP-1 Therapeutics…From Diabetes to Obesity and Beyond” and seeks to focus on the drug delivery challenge.

Industry experts will talk through the bioavailability challenge, and offer perspectives on how pharma have successfully addressed this through molecule design and optimization of drug product performance through iterative clinical assessment, before describing how the initial GLP1 therapeutics have stimulated other drug developers to expand into analogous mechanisms of action and small molecule therapeutics

Reasons to listen:

  • Building on the first in our series “Development of Orally Delivered GLP-1 Therapeutics…From Diabetes to Obesity and Beyond”
  • Learn about the biopharmaceutic considerations for oral GLP1 peptide therapeutics and how industry has innovated to overcome them
  • Hear about the health economic considerations of oral peptide delivery
  • Get an overview of other developments outside GLP1 peptides to address the obesity therapeutic area

Unable to attend due to a scheduling conflict?  Register now and we will share the content with you afterwards.

Register
Times

October 31, 2024

8:00 am PDT | 11:00 am EDT | 3:00 pm GMT

Meet our presenters:

Dr. Andrew Lewis

Chief Scientific Officer

Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...

About Andrew
Dr. Andrew Parker

Senior Drug Development Consultant

Dr. Andrew Parker has two decades of experience in the pharmaceutical industry, spanning from preclinical development, through ear...

About Andrew

Missed our 1st webinar?

Our team shares insight on how the GLP-1 landscape has evolved. Catch-up on our first webinar, now available to watch on-demand.

Quotient Sciences Logo
GLP1, Oral Peptides, Dr. Andy Lewis, Dr. Stuart Mair

On-Demand: Development of Orally Delivered GLP-1 Therapeutics …From Diabetes to Obesity and Beyond

18 July 2024 Watch On-Demand

Latest news from Quotient Sciences

Articles & Publications, Dr. Andy Lewis, AI, Clinical Trials The Future of Pharma: How AI is Transforming the Industry By: Dr. Andrew Lewis
Read More
formulation development, GLP-1, Peptides, Dr. Andy Lewis, Dr. Andrew Parker Video Interview: Dr. Andrew Lewis and Dr. Andrew Parker Speak with Manufacturing Chemist at CPHI Milan
Read More
Get in touch
Humanity can't afford to wait, so neither can we.